Answers are grounded in this paper and cite their sources.
Haemophilia A and B are X-linked inherited bleeding disorders caused by quantitative or qualitative deficiencies of coagulation factors VIII and IX, respectively. Understanding the underlying genetic pathogenesis and its variants is of paramount importance for current treatment targets, such as gene therapy. The current comprehensive review synthesizes the current evidence of molecular pathogenesis of haemophilia A and B, while it presents the therapeutic strategies, their limitations and future directions. Advances in molecular genetics have defined a highly heterogeneous mutational spectrum. Recurrent F8 inversions (intron 22 and 1) dominate severe phenotypes, while null mutations (nonsense, frameshift) are strongly associated with increased inhibitor risk. Conversely, missense variants predominantly underlie mild-to-moderate forms, and the identification of gain-of-function variants has directly informed next-generation therapeutic design. Clinically, strategies have transitioned from episodic replacement to individualized prophylaxis with ultra-long-acting concentrates and non-factor mimetics (emicizumab), which effectively prevent joint disease even in the presence of inhibitors. Furthermore, adeno-associated viral-mediated gene therapy offers a path toward a functional cure through sustained endogenous factor expression, although the long-term durability of FVIII expression and hepatic safety remain the primary current challenges. This review bridges the gap between the complex molecular landscape of haemophilia and the latest therapeutic breakthroughs. By linking specific genotypes to clinical outcomes and inhibitor risk, it provides a framework for precision management using factor, non-factor, and gene-based strategies in the current clinical landscape.
No takes yet. Share an insight, caveat, or question.
Bolou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: